Article Details

Pfizer's GBS6 receives FDA Breakthrough Therapy Designation

Retrieved on: 2022-09-08 16:37:36

Tags for this article:

Click the tags to see associated articles and topics

Pfizer's GBS6 receives FDA Breakthrough Therapy Designation. View article details on HISWAI: https://www.pharmaceutical-business-review.com/news/pfizer-gbs6-fda-breakthrough-therapy/

Excerpt

The US FDA has granted Breakthrough Therapy Designation to Pfizer's GBS6 or PF-06760805 to prevent invasive Group B Streptococcus (GBS) disease.

Article found on: www.pharmaceutical-business-review.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up